P275 Comparing Clinically Relevant Improvement With Umeclidinium/Vilanterol and Tiotropium/Olodaterol in Symptomatic Copd: A Randomised Non-Inferiority Crossover Trial

doi 10.1136/thoraxjnl-2017-210983.473
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

BMJ Publishing Group Ltd and British Thoracic Society

Related search

Tiotropium + Olodaterol Shows Clinically Meaningful Improvements in Quality of Life

Respiratory Medicine
PulmonaryRespiratory Medicine
2015English

Reduction in All-Cause Mortality With Fluticasone Furoate/Umeclidinium/Vilanterol in COPD Patients

American Journal of Respiratory and Critical Care Medicine
PulmonaryCritical CareRespiratory MedicineIntensive Care Medicine
2020English

Pharmacokinetics and Tolerability of Inhaled Umeclidinium and Vilanterol Alone and in Combination in Healthy Chinese Subjects: A Randomized, Open-Label, Crossover Trial

PLoS ONE
Multidisciplinary
2015English

Characteristics of Patients With and Without COPD Exacerbations During the Tiotropium + Olodaterol TONADO Studies

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2016English

Evidence-Based Review of Data on the Combination Inhaler Umeclidinium/Vilanterol in Patients With COPD

International Journal of COPD
EnvironmentalPublic HealthHealth PolicyMedicinePulmonaryRespiratory MedicineOccupational Health
2019English

Study Design Considerations in a Large COPD Trial Comparing Effects of Tiotropium With Salmeterol on Exacerbations

International Journal of COPD
EnvironmentalPublic HealthHealth PolicyMedicinePulmonaryRespiratory MedicineOccupational Health
2009English

Patient Considerations in the Treatment of COPD: Focus on the New Combination Inhaler Umeclidinium/Vilanterol

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2015English

A Randomised Trial of Fluticasone Furoate/Vilanterol (50/25 Μg; 100/25 Μg) on Lung Function in COPD

Respiratory Medicine
PulmonaryRespiratory Medicine
2013English

Efficacy and Safety of Once-Daily QVA149 Compared With the Free Combination of Once-Daily Tiotropium Plus Twice-Daily Formoterol in Patients With Moderate-To-Severe COPD (QUANTIFY): A Randomised, Non-Inferiority Study

Thorax
PulmonaryRespiratory Medicine
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy